Beverages made from vine leaves: Sustainable drinking pleasure based on
agricultural side streams

EQS-News: BRAIN Biotech AG / Key word(s): Alliance/Sustainability
Beverages made from vine leaves: Sustainable drinking pleasure based on
agricultural side streams

14.03.2024 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Beverages made from vine leaves: Sustainable drinking pleasure based on
agricultural side streams

  * BRAIN Biotech, Tropical Viticulture Consultants, Zukunftsweine and
    Provadis Hochschule jointly develop sustainable, non-alcoholic beverages
    from agricultural side streams

  * Consortium reaps benefits of new grape varieties adapted to climate
    change

  * Life cycle analysis and technical-economic analysis accompany different
    process variants

Zwingenberg, Mainz, Frankfurt, Friedrichsdorf (Germany), 14 March 2024 - At
the beginning of the year, a multidisciplinary German consortium of
biotechnologists, oenologists, winemakers and sustainability experts started
work on an innovation project funded by the German Federal Ministry of
Education and Research (BMBF): The "SusBev" (for "Sustainable Beverages")
project is a sub-project of the "Bioeconomy Innovation Space in Metropolitan
Regions" (BioBall) - and thus one of four initiatives in the focus of the
BMBF's National Research Strategy Bioeconomy 2030.

The aim of the "SusBev" project is to use and ferment agricultural residues
and side streams from viticulture and other regional agricultural processes
to produce healthy and tasty beverages and food.

Harnessing flavors from vine leaves

In their first project, the researchers are working with wine experts to use
the leaves of new grape varieties adapted to climate change to make
wine-like drinks. The vine leaves and shoots of these varieties, which have
not yet been used as a raw material, are suitable because they have an
attractive, varietal flavor (like the berries from which wine is made). In
addition, their resistance to fungal attack means that the plants require
less pesticide treatment, making them safe for consumption.

BRAIN Biotech AG, Tropical Viticulture Consultants (TVC), Zukunftsweine GmbH
(ZW) and Provadis Hochschule are participating in the SusBev project. In
particular, TVC provides expertise in the selection, harvesting and
processing of suitable side streams. BRAIN Biotech is responsible for the
selection and optimization of suitable microorganisms (starter cultures) as
well as the basic establishment of the bioprocess on a laboratory scale. ZW
and TVC transfer the laboratory results and test them in the winery. ZW will
also support product development from a market perspective and develop a
product brand profile. Provadis University of Applied Sciences will conduct
a life cycle analysis to assess the environmental impact and a technical and
economic analysis for the different process variants.

BMBF is funding the project "Innovationsraum: BioBall - SusBev - nachhaltige
Getränke und Lebensmittel auf Basis landwirtschaftlicher Seitenströme"
(funding code: 031B1476A) on a pro rata basis for the benefit of the funding
recipients over a period of two years. The grantees will invest their own
funds in the amount of the grant to successfully achieve the project
objectives - starter cultures, production processes and prototypes.

+++

About BRAIN Biotech

BRAIN Biotech AG is a leading European supplier of bio-based products and
solutions such as enzymes and proteins, microbial production strains,
natural compounds and biotechnological solutions for more sustainable
industrial processes. The company focuses on the fields of nutrition, health
and environment.

BRAIN Biotech AG is the parent company of the international BRAIN Biotech
Group. The Group's business activities are divided into three segments: The
BioProducts segment comprises the product business with specialty enzymes
and other proteins, for which the Group operates fermentation facilities in
the United Kingdom and production facilities in continental Europe and the
United States. The BioScience segment offers research-intensive custom
solutions based on enzyme technology, strain development, bioprocess
development and natural product screening. The BioIncubator segment conducts
its own R&D projects or those initiated with partners with high value-added
potential. A particularly promising incubator project is the development of
the Company's own CRISPR-based gene editing technology platform, which is
currently being established and expanded by Akribion Genomics (in foundation
planning).

Through its own R&D activities, BRAIN Biotech Group is continuously
expanding its product portfolio in the field of specialty enzymes and small
molecules. The latter are the starting point for screenings, e.g. for novel
drug candidates for pharmaceutical applications.

BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt
Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities
identification number: ISIN DE0005203947 / WKN 520394). The company employs
approximately 330 people and generated revenues of EUR 55.3 million in the
fiscal year 2022/23.

For more information, please visit: https://www.brain-biotech.com, LinkedIn,
Threads and YouTube.

Contact Media
Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Contact Investor Relations
Martina Schuster
Investor Relations
Phone: +49 6251 9331-69
Email: ms@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN Biotech AG, and are based on information currently available to the
management.

Forward-looking statements are no guarantees of future performance, and
entail both known and unknown risks as well as uncertainties that could
cause actual results, performance or events to differ materially from those
expressed or implied in such statements. Numerous factors exist that could
influence the future performance of and future developments at BRAIN Biotech
AG and the BRAIN Biotech Group. Such factors include, but are not limited
to, changes in the general economic and competitive environment, risks
associated with capital markets, currency exchange rate fluctuations,
changes in international and national laws and regulations, in particular
with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any
forward-looking statements.


---------------------------------------------------------------------------

14.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        BRAIN Biotech AG
                   Darmstädter Straße 34-36
                   64673 Zwingenberg
                   Germany
   Phone:          +49 (0) 62 51 / 9331-0
   Fax:            +49 (0) 62 51 / 9331-11
   E-mail:         ir@brain-biotech.com
   Internet:       www.brain-biotech.com
   ISIN:           DE0005203947
   WKN:            520394
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1858225

End of News EQS News Service
---------------------------------------------------------------------------

1858225 14.03.2024 CET/CEST